In this supplement we added a new drug monograph for LEVOSIMENDAN, NATALIZUMAB, NIVOLUMAB, NUSINERSEN, OCRELIZUMAB, OMADACYCLINE, PEMBROLIZUMAB, and VEDOLIZUMAB.
We added new stability information to these existing drug monographs: AMIFOSTINE, AMINOPHYLLINE, BUPIVACAINE HYDROCHLORIDE, CARBOPLATIN, CHLORAMPHENICOL SODIUM SUCCINATE, CEFOTETAN DISODIUM, CORTICOTROPIN, TRASTUZUMAB, and VALPROATE SODIUM.
In addition, new compatibility information is reported for these drugs: DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, FENTANYL CITRATE, MIDAZOLAM HYDROCHLORIDE, MILRINONE LACTATE, NITROGLYCERINE, NITROPRUSSIDE SODIUM, NOREPINEPHRINE BITARTRATE, REMIFENTANIL HYDROCHLORIDE, ROCURONIUM BROMIDE, SODIUM THIOSULFATE, VASOPRESSIN, and VECURONIUM BROMIDE.